Insmed (NASDAQ:INSM) Shares Gap Up – Here’s Why

Insmed, Inc. (NASDAQ:INSM) gapped up prior to trading on Friday . The stock had previously closed at $170.27, but opened at $185.02. Insmed shares last traded at $176.1910, with a volume of 1,333,602 shares changing hands.

Insmed News Summary

Here are the key news stories impacting Insmed this week:

• Positive Sentiment: Commercial momentum — Management reported unaudited results showing BRINSUPRI (brensocatib) generated roughly $144.6M in its first full quarter and ~ $172.7M for full‑year 2025; ARIKAYCE delivered ~ $433.8M in 2025, exceeding prior guidance, and company expects 2026 ARIKAYCE revenue of $450M–$470M. Insmed Provides Business Update
• Neutral Sentiment: Updated revenue guidance — Insmed issued FY guidance implying ~ $606.4M in revenue (above consensus ~$520.7M), a positive sign for sales but the EPS guidance entry was unclear; investors will watch forthcoming formal guidance disclosures. Guidance Detail
• Neutral Sentiment: Pipeline timing and R&D cadence — Topline from the ENCORE Phase 3 (ARIKAYCE) is now expected March–April 2026 and CEDAR (brensocatib in HS) in Q2 2026; Insmed also initiated a Phase 3 (PALM‑ILD) and plans additional Phase 3 starts in 2026, which are material catalysts but raise near‑term execution and spend risk. Pipeline Update
• Neutral Sentiment: Media attention — Jim Cramer highlighted Insmed as “worth keeping an eye on,” which can lift retail interest but is not a substitute for fundamentals. Jim Cramer Item
• Negative Sentiment: Heavy insider selling — Multiple executives (CEO, CFO, COO and others) sold shares Jan. 6–8, including repeated transactions by Michael Alexander Smith; coverage cites roughly $15.3M of insider sales, which can signal profit‑taking and depress sentiment. Insider Selling Report
• Negative Sentiment: Investor litigation alert — Pomerantz LLP has opened an investor investigation involving Insmed, introducing legal and reputational uncertainty until details are clarified. Pomerantz Investigation

Analyst Ratings Changes

Several research firms have recently weighed in on INSM. Wedbush set a $203.00 target price on Insmed in a report on Thursday, December 18th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Insmed in a research note on Wednesday, October 8th. HC Wainwright lowered their target price on shares of Insmed from $240.00 to $230.00 and set a “buy” rating on the stock in a research report on Thursday, December 18th. Bank of America upped their price target on shares of Insmed from $142.00 to $187.00 and gave the company a “buy” rating in a research report on Monday, October 27th. Finally, Rothschild Redb raised shares of Insmed to a “strong-buy” rating in a research report on Thursday, December 4th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $205.64.

Insmed Price Performance

The company’s 50 day simple moving average is $190.31 and its 200-day simple moving average is $151.37. The company has a market capitalization of $37.60 billion, a price-to-earnings ratio of -28.45 and a beta of 1.08. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59.

Insmed (NASDAQ:INSM) last issued its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.40). The business had revenue of $142.34 million during the quarter, compared to analyst estimates of $114.33 million. Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The company’s revenue was up 52.4% on a year-over-year basis. During the same quarter last year, the firm posted ($1.27) earnings per share. On average, equities research analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Insmed news, CFO Sara Bonstein sold 1,447 shares of the company’s stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $174.17, for a total value of $252,023.99. Following the completion of the transaction, the chief financial officer directly owned 80,506 shares of the company’s stock, valued at $14,021,730.02. This represents a 1.77% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, insider Michael Alexander Smith sold 1,053 shares of the stock in a transaction dated Thursday, January 8th. The shares were sold at an average price of $174.17, for a total value of $183,401.01. Following the completion of the transaction, the insider directly owned 57,037 shares of the company’s stock, valued at $9,934,134.29. This represents a 1.81% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 266,885 shares of company stock valued at $49,348,559. Corporate insiders own 3.00% of the company’s stock.

Institutional Trading of Insmed

Large investors have recently modified their holdings of the company. CIBC Private Wealth Group LLC raised its stake in Insmed by 42.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company’s stock valued at $26,000 after acquiring an additional 53 shares in the last quarter. Kingsview Wealth Management LLC boosted its holdings in shares of Insmed by 2.7% in the third quarter. Kingsview Wealth Management LLC now owns 2,321 shares of the biopharmaceutical company’s stock valued at $334,000 after acquiring an additional 60 shares in the last quarter. Choreo LLC boosted its holdings in shares of Insmed by 2.9% in the third quarter. Choreo LLC now owns 2,319 shares of the biopharmaceutical company’s stock valued at $334,000 after acquiring an additional 65 shares in the last quarter. Spire Wealth Management increased its stake in shares of Insmed by 11.5% during the third quarter. Spire Wealth Management now owns 777 shares of the biopharmaceutical company’s stock valued at $112,000 after acquiring an additional 80 shares during the period. Finally, MassMutual Private Wealth & Trust FSB raised its holdings in Insmed by 59.6% during the third quarter. MassMutual Private Wealth & Trust FSB now owns 217 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 81 shares in the last quarter.

About Insmed

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.